GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (FRA:PA8) » Definitions » Momentum Rank

Paion Ag (FRA:PA8) Momentum Rank : 0 (As of Jun. 06, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Momentum Rank?

Paion Ag has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Paion Ag Momentum Rank Related Terms

Thank you for viewing the detailed overview of Paion Ag's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (FRA:PA8) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.

Paion Ag (FRA:PA8) Headlines

No Headlines